The prognostic value of (123)I-mIBG SPECT cardiac imaging in heart failure patients: a systematic review

This systematic review aimed to evaluate the prognostic value of Iodine123 Metaiodobenzylguanidine ((123)I-mIBG) SPECT myocardial imaging in patients with heart failure (HF) and to assess whether semi-quantitative SPECT scores can be useful for accurate risk stratification concerning arrhythmic event (AE) and sudden cardiac death (SCD) in this cohort. A systematic literature search of studies published until November 2020 regarding the application of (123)I-mIBG SPECT in HF patients was performed, in Pubmed, Scopus, Medline, Central (Cochrane Library) and Web Of Science databases, including the words “MIBG”, “metaiodobenzylguanidine”, “heart”, “spect”, and “tomographic”. The included studies had to correlate (123)I-mIBG SPECT scores with endpoints such as overall survival and prevention of AE and SCD in HF patients. According to the sixteen studies included, the analysis showed that 123I-mIBG SPECT scores, such as summed defect score (SDS), regional wash-out (rWO), and regional myocardial tracer uptake, could have a reliable prognostic value in patients with HF. An increased SDS or rWO, as well as a reduced (123)I-mIBG myocardial uptake, have proven to be effective in predicting AE- and SCD-specific risk in HF patients. Despite achieved results being promising, a more reproducible standardized method for semi-quantitative analysis and further studies with larger cohort are needed for (123)I-mIBG SPECT myocardial imaging to be as reliable and, thus, accepted as the conventional (123)I-mIBG planar myocardial imaging. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s12350-020-02501-w) contains supplementary material, which is available to authorized users.